Literature DB >> 26198879

MRI in the Diagnosis and Monitoring of Multiple Sclerosis: An Update.

M P Wattjes1, M D Steenwijk2, M Stangel3.   

Abstract

Magnetic resonance imaging (MRI) is the most powerful tool for the early (differential) diagnosis of multiple sclerosis (MS) and has been part of the International Panel criteria (2001, 2005, 2010) for more than 10 years. The role of brain and spinal cord MRI in the diagnosis of MS is well established. New MR techniques and markers will further improve the diagnostic value in a research and clinical routine setting. In addition to diagnosis, MRI is widely used for prognostic evaluation as well as treatment efficacy and safety monitoring. This field has gained importance with the introduction of new MS therapeutics. Therefore, the scope of MRI-guided MS disease monitoring has been widened to include rigorous treatment monitoring aiming at "no evidence of disease activity (NEDA)". Next, safety monitoring of treated MS patients has become major concern to enable early detection of opportunistic infections such as progressive multifocal leukoencephalopathy (PML). Driven by these new developments, recently published expert panel guidelines stressed the need for standardized imaging protocols and targeted specialized imaging markers for MS diagnosis and disease monitoring. This review article aims to give an update on the role of MRI in the diagnosis and monitoring of MS with particular emphasis to treatment efficacy and safety, both in clinical practice and in research.

Entities:  

Keywords:  Disease monitoring; MRI; Multiple sclerosis; PML; Safety monitoring

Mesh:

Year:  2015        PMID: 26198879     DOI: 10.1007/s00062-015-0430-y

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


  54 in total

1.  Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis.

Authors:  M Filippi; M A Rocca; M Calabrese; M P Sormani; F Rinaldi; P Perini; G Comi; P Gallo
Journal:  Neurology       Date:  2010-11-30       Impact factor: 9.910

2.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

Authors:  Maria Pia Sormani; Douglas L Arnold; Nicola De Stefano
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

3.  MRI pattern in asymptomatic natalizumab-associated PML.

Authors:  Mike P Wattjes; Anke Vennegoor; Martijn D Steenwijk; Marlieke de Vos; Joep Killestein; Bob W van Oosten; Jop Mostert; Dorine A Siepman; Wiebe Moll; Alex E L van Golde; Stephan T F M Frequin; Nancy D Richert; Frederik Barkhof
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-09-09       Impact factor: 10.154

4.  What drives MRI-measured cortical atrophy in multiple sclerosis?

Authors:  V Popescu; R Klaver; P Voorn; Y Galis-de Graaf; D L Knol; J W R Twisk; A Versteeg; G J Schenk; P Van der Valk; F Barkhof; H E De Vries; H Vrenken; J J G Geurts
Journal:  Mult Scler       Date:  2015-01-12       Impact factor: 6.312

5.  Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Authors:  Ann M Arvin; Jerry S Wolinsky; Ludwig Kappos; Michele I Morris; Anthony T Reder; Carlo Tornatore; Anne Gershon; Michael Gershon; Myron J Levin; Mauritz Bezuidenhoudt; Norman Putzki
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 6.  Treatment optimization in MS: Canadian MS Working Group updated recommendations.

Authors:  Mark S Freedman; Daniel Selchen; Douglas L Arnold; Alexandre Prat; Brenda Banwell; Michael Yeung; David Morgenthau; Yves Lapierre
Journal:  Can J Neurol Sci       Date:  2013-05       Impact factor: 2.104

Review 7.  Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Authors:  V Wee Yong
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

8.  Measures in the first year of therapy predict the response to interferon beta in MS.

Authors:  J Río; J Castilló; A Rovira; M Tintoré; J Sastre-Garriga; A Horga; C Nos; M Comabella; X Aymerich; X Montalbán
Journal:  Mult Scler       Date:  2009-07       Impact factor: 6.312

9.  Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.

Authors:  Gijsbert J A Nagtegaal; Christoph Pohl; Mike P Wattjes; Hanneke E Hulst; Mark S Freedman; Hans-Peter Hartung; David Miller; Xavier Montalban; Ludwig Kappos; Gilles Edan; Dirk Pleimes; Karola Beckman; Brigitte Stemper; Christoph H Polman; Rupert Sandbrink; Frederik Barkhof
Journal:  Mult Scler       Date:  2013-07-10       Impact factor: 6.312

10.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

View more
  25 in total

1.  The relationship of multiple sclerosis and cerebral developmental venous anomaly with an advantageous role in the multiple sclerosis diagnosis.

Authors:  Mohammad Reza Sasani; Ali Reza Dehghan; Nikseresht Ali Reza
Journal:  Iran J Neurol       Date:  2017-10-07

Review 2.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 1-Mechanisms, Efficacy, and Safety.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-13       Impact factor: 3.825

Review 3.  Defining Disease Activity and Response to Therapy in MS.

Authors:  Ulrike W Kaunzner; Mais Al-Kawaz; Susan A Gauthier
Journal:  Curr Treat Options Neurol       Date:  2017-05       Impact factor: 3.598

Review 4.  MRI in the assessment and monitoring of multiple sclerosis: an update on best practice.

Authors:  Ulrike W Kaunzner; Susan A Gauthier
Journal:  Ther Adv Neurol Disord       Date:  2017-05-12       Impact factor: 6.570

Review 5.  Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

Authors:  C McNamara; G Sugrue; B Murray; P J MacMahon
Journal:  AJNR Am J Neuroradiol       Date:  2017-04-20       Impact factor: 3.825

Review 6.  MRI and multiple sclerosis--the evolving role of MRI in the diagnosis and management of MS: the radiologist's perspective.

Authors:  Alexis M Cahalane; Hugh Kearney; Yvonne M Purcell; Christopher McGuigan; Ronan P Killeen
Journal:  Ir J Med Sci       Date:  2017-11-25       Impact factor: 1.568

7.  Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Authors:  Natalia Gonzalez Caldito; Shiv Saidha; Elias S Sotirchos; Blake E Dewey; Norah J Cowley; Jeffrey Glaister; Kathryn C Fitzgerald; Omar Al-Louzi; James Nguyen; Alissa Rothman; Esther Ogbuokiri; Nicholas Fioravante; Sydney Feldman; Ohemaa Kwakyi; Hunter Risher; Dorlan Kimbrough; Teresa C Frohman; Elliot Frohman; Laura Balcer; Ciprian Crainiceanu; Peter C M Van Zijl; Ellen M Mowry; Daniel S Reich; Jiwon Oh; Dzung L Pham; Jerry Prince; Peter A Calabresi
Journal:  Brain       Date:  2018-11-01       Impact factor: 13.501

Review 8.  Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications.

Authors:  Mark S Igra; David Paling; Mike P Wattjes; Daniel J A Connolly; Nigel Hoggard
Journal:  Br J Radiol       Date:  2017-04-26       Impact factor: 3.039

Review 9.  [Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017].

Authors:  O Aktas; M P Wattjes; M Stangel; H-P Hartung
Journal:  Nervenarzt       Date:  2018-12       Impact factor: 1.214

10.  Increasing the sensitivity of MRI for the detection of multiple sclerosis lesions by long axial coverage of the spinal cord: a prospective study in 119 patients.

Authors:  Michael O Breckwoldt; Johann Gradl; Stefan Hähnel; Thomas Hielscher; Brigitte Wildemann; Ricarda Diem; Michael Platten; Wolfgang Wick; Sabine Heiland; Martin Bendszus
Journal:  J Neurol       Date:  2016-12-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.